Our Mission
To use Susavion’s patented MultiValent Peptide Mimetic (MVPM) Technology platform to harness the innate power of the immune system to combat diseases with non-toxic, safe and effective treatments.
At Susavion, we pride ourselves on doing things differently. We’re at the forefront of scientific innovation, leading the charge in the effort to solve some of healthcare’s most intractable problems. Our revolutionary therapy is safe and nontoxic, and we care about the people our research will benefit—always balancing our cutting-edge technology with our humanity.
Company Overview
-
Privately owned
-
Incorporated in 2006
-
15 issued patents, 3 pending
-
12 publications in peer-reviewed journals
Our Team
Gregory R. Wolfe, Ph.D. Chief Executive Officer and Cofounder
Cofounder and Chief Executive Officer at Susavion Biosciences. Dr. Wolfe also serves as a senior oncology consultant at Kantar Health, where he provides a wide range of business consulting services to both large and small pharmaceutical companies.
Building on his experience at Kantar Health, he cofounded Susavion Biosciences with the vision of advancing technology based on the discovery of multivalent, bioactive peptides that mimic carbohydrate ligands of lectin-type receptors for use as therapeutic modulators of the immune system.
Laura L. Eggink, Ph.D. President and Cofounder
A former Assistant Professor Research of Biomedicine and Biotechnology at Arizona State University, Laura is a leading researcher on peptide mimetics.
Also an expert on cell signaling, she has worked with a number of experimental models ranging from chloroplasts to macrophages. Dr. Eggink, the inventor of 15 patents and 3 applications, is a leading investigator demonstrating the feasibility of modulating the immune system with peptide mimetics of carbohydrates.
J. Kenneth Hoober, Ph.D. Chief Scientific Officer and Cofounder
As the Chair of Biochemistry, Temple Univ. School of Medicine and most recently, Chair in the School of Life Sciences, Arizona State University, Dr. Hoober has contributed to over 100 research publications.
Dr. Hoober has devoted much of his career to understanding the mechanisms of membrane biogenesis. He is particularly known for his contributions to the field of chloroplast membrane protein chemistry and synthesis. Dr. Hoober was involved in the early work on GcMAF and its ability to stimulate the activation of macrophages.